anti-siglec-9

**anti-siglec-9** is a nonspecific term referring to experimental antibodies directed against sialic acid-binding immunoglobulin-like lectin 9, an inhibitory immune checkpoint receptor expressed on myeloid cells, natural killer cells, and some T-cell populations. In the literature, anti-Siglec-9 antibodies are generally described as preclinical monoclonal antibodies intended to block Siglec-9 engagement by tumor-associated sialoglycans, thereby relieving inhibitory ITIM-mediated signaling and enhancing anti-tumor immune responses. Because the query does not identify a single defined molecule, clone, developer program, or clinical candidate, it is best treated as a target-directed antibody concept rather than a uniquely identifiable drug asset; published work includes preclinical blocking antibodies from The Wistar Institute, but no clearly established marketed product or universally accepted canonical therapeutic name was identified.

Other names

anti-siglec-9anti-siglec9anti-siglec 9anti-Siglec-9 antibodyanti-Siglec9 antibodyanti-Siglec 9 antibodySiglec-9 blocking antibodySiglec9 blocking antibodySiglec 9 blocking antibody